KR20020015379A - 엠이케이 억제제를 사용하는 만성 동통의 치료방법 - Google Patents
엠이케이 억제제를 사용하는 만성 동통의 치료방법 Download PDFInfo
- Publication number
- KR20020015379A KR20020015379A KR1020027000665A KR20027000665A KR20020015379A KR 20020015379 A KR20020015379 A KR 20020015379A KR 1020027000665 A KR1020027000665 A KR 1020027000665A KR 20027000665 A KR20027000665 A KR 20027000665A KR 20020015379 A KR20020015379 A KR 20020015379A
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- phenyl
- iodo
- phenylamino
- fluoro
- Prior art date
Links
- 208000002193 Pain Diseases 0.000 title claims abstract description 75
- 238000000034 method Methods 0.000 title claims abstract description 52
- 208000000094 Chronic Pain Diseases 0.000 title claims abstract description 21
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 title claims description 23
- -1 hydrocarbon radicals Chemical class 0.000 claims description 301
- 150000001875 compounds Chemical class 0.000 claims description 74
- 230000036407 pain Effects 0.000 claims description 50
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 35
- 125000000217 alkyl group Chemical group 0.000 claims description 23
- 150000002148 esters Chemical class 0.000 claims description 23
- 229940124647 MEK inhibitor Drugs 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 20
- 208000004296 neuralgia Diseases 0.000 claims description 17
- 208000021722 neuropathic pain Diseases 0.000 claims description 16
- ZZLTXWMPUKJTFS-UHFFFAOYSA-N 2-hydroxy-3h-oxadiazole Chemical compound ON1NC=CO1 ZZLTXWMPUKJTFS-UHFFFAOYSA-N 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 125000000304 alkynyl group Chemical group 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- 208000027418 Wounds and injury Diseases 0.000 claims description 9
- 125000003342 alkenyl group Chemical group 0.000 claims description 9
- 230000001684 chronic effect Effects 0.000 claims description 9
- 230000006378 damage Effects 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 208000004550 Postoperative Pain Diseases 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 229910004013 NO 2 Inorganic materials 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 7
- 208000014674 injury Diseases 0.000 claims description 7
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims description 6
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 5
- 125000001246 bromo group Chemical group Br* 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- QYIPXKFVULIACW-UHFFFAOYSA-N 5-[3,4-difluoro-2-(4-iodo-2-methylanilino)phenyl]-1,2-dihydro-1,2,4-triazole-3-thione Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=CC=C1C1=NN=C(S)N1 QYIPXKFVULIACW-UHFFFAOYSA-N 0.000 claims description 4
- XECMFJLNUYXNMZ-UHFFFAOYSA-N 5-[3,4-difluoro-2-(4-iodo-2-methylanilino)phenyl]-1h-1,2,4-triazol-3-amine Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=CC=C1C1=NN=C(N)N1 XECMFJLNUYXNMZ-UHFFFAOYSA-N 0.000 claims description 4
- 208000000412 Avitaminosis Diseases 0.000 claims description 4
- 208000037157 Azotemia Diseases 0.000 claims description 4
- 239000004215 Carbon black (E152) Substances 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 230000008602 contraction Effects 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 229930195733 hydrocarbon Natural products 0.000 claims description 4
- 208000003532 hypothyroidism Diseases 0.000 claims description 4
- 230000002989 hypothyroidism Effects 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- MPSUGQWRVNRJEE-UHFFFAOYSA-N triazol-1-amine Chemical compound NN1C=CN=N1 MPSUGQWRVNRJEE-UHFFFAOYSA-N 0.000 claims description 4
- 208000009852 uremia Diseases 0.000 claims description 4
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 3
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims description 3
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 claims description 3
- 206010021135 Hypovitaminosis Diseases 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 206010047115 Vasculitis Diseases 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 claims description 3
- 210000003169 central nervous system Anatomy 0.000 claims description 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 238000011542 limb amputation Methods 0.000 claims description 3
- 230000000451 tissue damage Effects 0.000 claims description 3
- 231100000827 tissue damage Toxicity 0.000 claims description 3
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- 208000030401 vitamin deficiency disease Diseases 0.000 claims description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- QEASJVYPHMYPJM-UHFFFAOYSA-N 1,2-dihydrotriazol-5-one Chemical compound OC1=CNN=N1 QEASJVYPHMYPJM-UHFFFAOYSA-N 0.000 claims description 2
- FVTJNFQCZSPAPJ-UHFFFAOYSA-N 1-[4-fluoro-2-(4-iodo-2-methylanilino)-5-nitrophenyl]-4-methyltetrazol-5-one Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=C([N+]([O-])=O)C=C1N1C(=O)N(C)N=N1 FVTJNFQCZSPAPJ-UHFFFAOYSA-N 0.000 claims description 2
- RGJVRVILAKALFK-UHFFFAOYSA-N 1-[4-fluoro-2-(4-iodo-2-methylanilino)phenyl]-4-methyltetrazol-5-one Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=CC=C1N1C(=O)N(C)N=N1 RGJVRVILAKALFK-UHFFFAOYSA-N 0.000 claims description 2
- QGDAAPPGTYAIIW-UHFFFAOYSA-N 2,3,4-trifluoro-n-(4-iodo-2-methylphenyl)-6-(2h-tetrazol-5-yl)aniline Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=C(F)C=C1C1=NN=NN1 QGDAAPPGTYAIIW-UHFFFAOYSA-N 0.000 claims description 2
- JVQDJRVZPPUWHQ-UHFFFAOYSA-N 2,3-difluoro-n-(4-iodo-2-methylphenyl)-6-(2h-tetrazol-5-yl)aniline Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=CC=C1C1=NN=NN1 JVQDJRVZPPUWHQ-UHFFFAOYSA-N 0.000 claims description 2
- RULVVSJRJXIGND-UHFFFAOYSA-N 2,4-bis(2-chloro-4-iodoanilino)-3-fluoro-5-nitrobenzoic acid Chemical group FC1=C(NC=2C(=CC(I)=CC=2)Cl)C(C(=O)O)=CC([N+]([O-])=O)=C1NC1=CC=C(I)C=C1Cl RULVVSJRJXIGND-UHFFFAOYSA-N 0.000 claims description 2
- VYSBJZZJRDWJGA-UHFFFAOYSA-N 2-(4,4-dimethyl-5h-1,3-oxazol-2-yl)-5-fluoro-n-(4-iodo-2-methylphenyl)aniline Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=CC=C1C1=NC(C)(C)CO1 VYSBJZZJRDWJGA-UHFFFAOYSA-N 0.000 claims description 2
- WQRGDLXRCFRGOQ-UHFFFAOYSA-N 3-[3,4,5-trifluoro-2-(4-iodo-2-methylanilino)phenyl]-2h-1,2-oxazol-5-one Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=C(F)C=C1C1=CC(=O)ON1 WQRGDLXRCFRGOQ-UHFFFAOYSA-N 0.000 claims description 2
- OKWVBTUWSSEFQJ-UHFFFAOYSA-N 3-[3,4-difluoro-2-(4-iodo-2-methylanilino)phenyl]-2h-1,2-oxazol-5-one Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=CC=C1C1=CC(=O)ON1 OKWVBTUWSSEFQJ-UHFFFAOYSA-N 0.000 claims description 2
- ZBHZDNXGSWNMOI-UHFFFAOYSA-N 3-[4-fluoro-2-(4-iodo-2-methylanilino)-5-nitrophenyl]-2h-1,2-oxazol-5-one Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=C([N+]([O-])=O)C=C1C1=CC(=O)ON1 ZBHZDNXGSWNMOI-UHFFFAOYSA-N 0.000 claims description 2
- VIDTXRFNAHTNJK-UHFFFAOYSA-N 3-[4-fluoro-2-(4-iodo-2-methylanilino)phenyl]-2h-1,2-oxazol-5-one Chemical group CC1=CC(I)=CC=C1NC1=CC(F)=CC=C1C1=CC(=O)ON1 VIDTXRFNAHTNJK-UHFFFAOYSA-N 0.000 claims description 2
- YGTAZAAYPMKQMA-UHFFFAOYSA-N 3-[5-bromo-3,4-difluoro-2-(4-iodo-2-methylanilino)phenyl]-2h-1,2-oxazol-5-one Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=C(Br)C=C1C1=CC(=O)ON1 YGTAZAAYPMKQMA-UHFFFAOYSA-N 0.000 claims description 2
- UPGDPKNDUGBHJO-UHFFFAOYSA-N 4-[3,4,5-trifluoro-2-(4-iodo-2-methylanilino)phenyl]-1,2-oxazol-3-one Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=C(F)C=C1C1=CON=C1O UPGDPKNDUGBHJO-UHFFFAOYSA-N 0.000 claims description 2
- DDOSQEBJCJFTSI-UHFFFAOYSA-N 4-[3,4,5-trifluoro-2-(4-iodo-2-methylanilino)phenyl]-1,2-thiazol-3-one Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=C(F)C=C1C1=CSN=C1O DDOSQEBJCJFTSI-UHFFFAOYSA-N 0.000 claims description 2
- WOLJKRQMWVGOCZ-UHFFFAOYSA-N 4-[3,4,5-trifluoro-2-(4-iodo-2-methylanilino)phenyl]-4h-1,2-oxazol-5-one Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=C(F)C=C1C1C(=O)ON=C1 WOLJKRQMWVGOCZ-UHFFFAOYSA-N 0.000 claims description 2
- BZHFBSLDGULCTM-UHFFFAOYSA-N 4-[3,4-difluoro-2-(4-iodo-2-methylanilino)phenyl]-1,2-oxazol-3-one Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=CC=C1C1=CON=C1O BZHFBSLDGULCTM-UHFFFAOYSA-N 0.000 claims description 2
- VVPPJZLDNIBPQW-UHFFFAOYSA-N 4-[3,4-difluoro-2-(4-iodo-2-methylanilino)phenyl]-1,2-thiazol-3-one Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=CC=C1C1=CSN=C1O VVPPJZLDNIBPQW-UHFFFAOYSA-N 0.000 claims description 2
- ZICMEXBGXFWOAD-UHFFFAOYSA-N 4-[3,4-difluoro-2-(4-iodo-2-methylanilino)phenyl]-2-methyl-1h-pyrazol-5-one Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=CC=C1C1=CN(C)N=C1O ZICMEXBGXFWOAD-UHFFFAOYSA-N 0.000 claims description 2
- JROAVHUBFWGXMF-UHFFFAOYSA-N 4-[3,4-difluoro-2-(4-iodo-2-methylanilino)phenyl]-4h-1,2-oxazol-5-one Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=CC=C1C1C(=O)ON=C1 JROAVHUBFWGXMF-UHFFFAOYSA-N 0.000 claims description 2
- GIGIQHHCOYTASR-UHFFFAOYSA-N 4-[4-fluoro-2-(4-iodo-2-methylanilino)-5-nitrophenyl]-1,2-oxazol-3-one Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=C([N+]([O-])=O)C=C1C1=CON=C1O GIGIQHHCOYTASR-UHFFFAOYSA-N 0.000 claims description 2
- HHDMWXPOIBGYHM-UHFFFAOYSA-N 4-[4-fluoro-2-(4-iodo-2-methylanilino)-5-nitrophenyl]-1,2-thiazol-3-one Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=C([N+]([O-])=O)C=C1C1=CSN=C1O HHDMWXPOIBGYHM-UHFFFAOYSA-N 0.000 claims description 2
- GKBNTEJRQLGWFH-UHFFFAOYSA-N 4-[4-fluoro-2-(4-iodo-2-methylanilino)phenyl]-1,2-oxazol-3-one Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=CC=C1C1=CON=C1O GKBNTEJRQLGWFH-UHFFFAOYSA-N 0.000 claims description 2
- XCEAAXNFYQTNRX-UHFFFAOYSA-N 4-[4-fluoro-2-(4-iodo-2-methylanilino)phenyl]-1,2-thiazol-3-one Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=CC=C1C1=CSN=C1O XCEAAXNFYQTNRX-UHFFFAOYSA-N 0.000 claims description 2
- ATIIDUMSUKPVSW-UHFFFAOYSA-N 4-[4-fluoro-2-(4-iodo-2-methylanilino)phenyl]-2-methyl-1h-pyrazol-5-one Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=CC=C1C1=CN(C)N=C1O ATIIDUMSUKPVSW-UHFFFAOYSA-N 0.000 claims description 2
- FDKCGBRXTKECRT-UHFFFAOYSA-N 4-[4-fluoro-2-(4-iodo-2-methylanilino)phenyl]-4h-1,2-oxazol-5-one Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=CC=C1C1C(=O)ON=C1 FDKCGBRXTKECRT-UHFFFAOYSA-N 0.000 claims description 2
- BYRWCWFJIUSCAW-UHFFFAOYSA-N 4-[5-bromo-3,4-difluoro-2-(4-iodo-2-methylanilino)phenyl]-1,2-oxazol-3-one Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=C(Br)C=C1C1=CON=C1O BYRWCWFJIUSCAW-UHFFFAOYSA-N 0.000 claims description 2
- HTSYSXSLJHYHEG-UHFFFAOYSA-N 4-[5-bromo-3,4-difluoro-2-(4-iodo-2-methylanilino)phenyl]-1,2-thiazol-3-one Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=C(Br)C=C1C1=CSN=C1O HTSYSXSLJHYHEG-UHFFFAOYSA-N 0.000 claims description 2
- ODMPNWXCSIYDGM-UHFFFAOYSA-N 4-[5-bromo-3,4-difluoro-2-(4-iodo-2-methylanilino)phenyl]-2-methyl-1h-pyrazol-5-one Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=C(Br)C=C1C1=CN(C)N=C1O ODMPNWXCSIYDGM-UHFFFAOYSA-N 0.000 claims description 2
- FJHIVVSXTRNKOO-UHFFFAOYSA-N 4-[5-bromo-3,4-difluoro-2-(4-iodo-2-methylanilino)phenyl]-4h-1,2-oxazol-5-one Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=C(Br)C=C1C1C(=O)ON=C1 FJHIVVSXTRNKOO-UHFFFAOYSA-N 0.000 claims description 2
- GVZOBHGQDYMLOM-UHFFFAOYSA-N 4-bromo-2,3-difluoro-n-(4-iodo-2-methylphenyl)-6-(2h-tetrazol-5-yl)aniline Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=C(Br)C=C1C1=NN=NN1 GVZOBHGQDYMLOM-UHFFFAOYSA-N 0.000 claims description 2
- POZBLOICDUEJOH-UHFFFAOYSA-N 5-[2-(2-amino-4-iodoanilino)-3,4-difluorophenyl]-1-methyltriazol-4-ol Chemical compound CN1N=NC(O)=C1C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1N POZBLOICDUEJOH-UHFFFAOYSA-N 0.000 claims description 2
- RHGLMCDRXHZKPZ-UHFFFAOYSA-N 5-[2-(2-amino-4-iodoanilino)-4-fluorophenyl]-1-methyltriazol-4-ol Chemical group CN1N=NC(O)=C1C1=CC=C(F)C=C1NC1=CC=C(I)C=C1N RHGLMCDRXHZKPZ-UHFFFAOYSA-N 0.000 claims description 2
- JBCJEIBYCOKDHF-UHFFFAOYSA-N 5-[3,4,5-trifluoro-2-(4-iodo-2-methylanilino)phenyl]-1,2-dihydro-1,2,4-triazol-3-one Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=C(F)C=C1C1=NN=C(O)N1 JBCJEIBYCOKDHF-UHFFFAOYSA-N 0.000 claims description 2
- ZKAUXPXXFYNVAF-UHFFFAOYSA-N 5-[3,4,5-trifluoro-2-(4-iodo-2-methylanilino)phenyl]-1,2-dihydro-1,2,4-triazole-3-thione Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=C(F)C=C1C1=NN=C(S)N1 ZKAUXPXXFYNVAF-UHFFFAOYSA-N 0.000 claims description 2
- MTZZXFIKCUBSPB-UHFFFAOYSA-N 5-[3,4,5-trifluoro-2-(4-iodo-2-methylanilino)phenyl]-1,2-dihydropyrazol-3-one Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=C(F)C=C1C1=CC(O)=NN1 MTZZXFIKCUBSPB-UHFFFAOYSA-N 0.000 claims description 2
- NWYZNCYPLDVQAW-UHFFFAOYSA-N 5-[3,4,5-trifluoro-2-(4-iodo-2-methylanilino)phenyl]-1,2-oxazol-3-one Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=C(F)C=C1C1=CC(O)=NO1 NWYZNCYPLDVQAW-UHFFFAOYSA-N 0.000 claims description 2
- ZRJQUKGUSJAEQR-UHFFFAOYSA-N 5-[3,4,5-trifluoro-2-(4-iodo-2-methylanilino)phenyl]-1,2-thiazol-3-one Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=C(F)C=C1C1=CC(O)=NS1 ZRJQUKGUSJAEQR-UHFFFAOYSA-N 0.000 claims description 2
- VUEDPIOQVJPKKV-UHFFFAOYSA-N 5-[3,4,5-trifluoro-2-(4-iodo-2-methylanilino)phenyl]-1,3,4-thiadiazol-2-amine Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=C(F)C=C1C1=NN=C(N)S1 VUEDPIOQVJPKKV-UHFFFAOYSA-N 0.000 claims description 2
- JFWLPLIRIUYILG-UHFFFAOYSA-N 5-[3,4,5-trifluoro-2-(4-iodo-2-methylanilino)phenyl]-3h-1,3,4-oxadiazole-2-thione Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=C(F)C=C1C1=NN=C(S)O1 JFWLPLIRIUYILG-UHFFFAOYSA-N 0.000 claims description 2
- PAFBJOBUVMWSRW-UHFFFAOYSA-N 5-[3,4,5-trifluoro-2-(4-iodo-2-methylanilino)phenyl]-3h-1,3,4-thiadiazol-2-one Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=C(F)C=C1C1=NN=C(O)S1 PAFBJOBUVMWSRW-UHFFFAOYSA-N 0.000 claims description 2
- JVDGOPGIZANNNS-UHFFFAOYSA-N 5-[3,4,5-trifluoro-2-(4-iodo-2-methylanilino)phenyl]-3h-1,3,4-thiadiazole-2-thione Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=C(F)C=C1C1=NN=C(S)S1 JVDGOPGIZANNNS-UHFFFAOYSA-N 0.000 claims description 2
- PWZDHDLDKBQMSH-UHFFFAOYSA-N 5-[3,4-difluoro-2-(4-iodo-2-methylanilino)phenyl]-1,2-dihydro-1,2,4-triazol-3-one Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=CC=C1C1=NN=C(O)N1 PWZDHDLDKBQMSH-UHFFFAOYSA-N 0.000 claims description 2
- PWOCQFXWCJLJQA-UHFFFAOYSA-N 5-[3,4-difluoro-2-(4-iodo-2-methylanilino)phenyl]-1,2-oxazol-3-one Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=CC=C1C1=CC(O)=NO1 PWOCQFXWCJLJQA-UHFFFAOYSA-N 0.000 claims description 2
- VTMWBHRBNZTMSE-UHFFFAOYSA-N 5-[3,4-difluoro-2-(4-iodo-2-methylanilino)phenyl]-1,2-thiazol-3-one Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=CC=C1C1=CC(O)=NS1 VTMWBHRBNZTMSE-UHFFFAOYSA-N 0.000 claims description 2
- CFBVQEZLISVQOX-UHFFFAOYSA-N 5-[3,4-difluoro-2-(4-iodo-2-methylanilino)phenyl]-1,3,4-oxadiazol-2-amine Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=CC=C1C1=NN=C(N)O1 CFBVQEZLISVQOX-UHFFFAOYSA-N 0.000 claims description 2
- KPGXOIWUBAUIQJ-UHFFFAOYSA-N 5-[3,4-difluoro-2-(4-iodo-2-methylanilino)phenyl]-1,3,4-thiadiazol-2-amine Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=CC=C1C1=NN=C(N)S1 KPGXOIWUBAUIQJ-UHFFFAOYSA-N 0.000 claims description 2
- URUXUUSWKYMMRR-UHFFFAOYSA-N 5-[3,4-difluoro-2-(4-iodo-2-methylanilino)phenyl]-3h-1,3,4-oxadiazole-2-thione Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=CC=C1C1=NN=C(S)O1 URUXUUSWKYMMRR-UHFFFAOYSA-N 0.000 claims description 2
- ICFOZMCFRHMZKD-UHFFFAOYSA-N 5-[3,4-difluoro-2-(4-iodo-2-methylanilino)phenyl]-3h-1,3,4-thiadiazol-2-one Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=CC=C1C1=NN=C(O)S1 ICFOZMCFRHMZKD-UHFFFAOYSA-N 0.000 claims description 2
- KNMDLUPXTQDNHJ-UHFFFAOYSA-N 5-[3,4-difluoro-2-(4-iodo-2-methylanilino)phenyl]-3h-1,3,4-thiadiazole-2-thione Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=CC=C1C1=NN=C(S)S1 KNMDLUPXTQDNHJ-UHFFFAOYSA-N 0.000 claims description 2
- QVDLZEGBOGIZDG-UHFFFAOYSA-N 5-[4-fluoro-2-(4-iodo-2-methylanilino)-5-nitrophenyl]-1,2-dihydropyrazol-3-one Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=C([N+]([O-])=O)C=C1C1=CC(O)=NN1 QVDLZEGBOGIZDG-UHFFFAOYSA-N 0.000 claims description 2
- NGKZPTSKUSNITC-UHFFFAOYSA-N 5-[4-fluoro-2-(4-iodo-2-methylanilino)-5-nitrophenyl]-1,2-oxazol-3-one Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=C([N+]([O-])=O)C=C1C1=CC(O)=NO1 NGKZPTSKUSNITC-UHFFFAOYSA-N 0.000 claims description 2
- FLTOBUAOCWCIMO-UHFFFAOYSA-N 5-[4-fluoro-2-(4-iodo-2-methylanilino)-5-nitrophenyl]-1,2-thiazol-3-one Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=C([N+]([O-])=O)C=C1C1=CC(O)=NS1 FLTOBUAOCWCIMO-UHFFFAOYSA-N 0.000 claims description 2
- KFEZKBOFUMYUOU-UHFFFAOYSA-N 5-[4-fluoro-2-(4-iodo-2-methylanilino)-5-nitrophenyl]-1,3,4-thiadiazol-2-amine Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=C([N+]([O-])=O)C=C1C1=NN=C(N)S1 KFEZKBOFUMYUOU-UHFFFAOYSA-N 0.000 claims description 2
- RXVJKZPEWXGYQH-UHFFFAOYSA-N 5-[4-fluoro-2-(4-iodo-2-methylanilino)-5-nitrophenyl]-1h-1,2,4-triazol-3-amine Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=C([N+]([O-])=O)C=C1C1=NN=C(N)N1 RXVJKZPEWXGYQH-UHFFFAOYSA-N 0.000 claims description 2
- UXOBRLHZBBDGRY-UHFFFAOYSA-N 5-[4-fluoro-2-(4-iodo-2-methylanilino)-5-nitrophenyl]-3h-1,3,4-oxadiazole-2-thione Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=C([N+]([O-])=O)C=C1C1=NN=C(S)O1 UXOBRLHZBBDGRY-UHFFFAOYSA-N 0.000 claims description 2
- PLHIYIVMGXBALK-UHFFFAOYSA-N 5-[4-fluoro-2-(4-iodo-2-methylanilino)-5-nitrophenyl]-3h-1,3,4-thiadiazol-2-one Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=C([N+]([O-])=O)C=C1C1=NN=C(O)S1 PLHIYIVMGXBALK-UHFFFAOYSA-N 0.000 claims description 2
- SBJZMEOHIODPCZ-UHFFFAOYSA-N 5-[4-fluoro-2-(4-iodo-2-methylanilino)-5-nitrophenyl]-3h-1,3,4-thiadiazole-2-thione Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=C([N+]([O-])=O)C=C1C1=NN=C(S)S1 SBJZMEOHIODPCZ-UHFFFAOYSA-N 0.000 claims description 2
- FNEGQYQGDVYILD-UHFFFAOYSA-N 5-[4-fluoro-2-(4-iodo-2-methylanilino)phenyl]-1,2-dihydro-1,2,4-triazol-3-one Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=CC=C1C1=NN=C(O)N1 FNEGQYQGDVYILD-UHFFFAOYSA-N 0.000 claims description 2
- YEFHFAQQWRVWEO-UHFFFAOYSA-N 5-[4-fluoro-2-(4-iodo-2-methylanilino)phenyl]-1,2-dihydro-1,2,4-triazole-3-thione Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=CC=C1C1=NN=C(S)N1 YEFHFAQQWRVWEO-UHFFFAOYSA-N 0.000 claims description 2
- DKGBUVAKILBEQF-UHFFFAOYSA-N 5-[4-fluoro-2-(4-iodo-2-methylanilino)phenyl]-1,2-dihydropyrazol-3-one Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=CC=C1C1=CC(O)=NN1 DKGBUVAKILBEQF-UHFFFAOYSA-N 0.000 claims description 2
- KYJDAVBVYZEVOJ-UHFFFAOYSA-N 5-[4-fluoro-2-(4-iodo-2-methylanilino)phenyl]-1,2-oxazol-3-one Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=CC=C1C1=CC(O)=NO1 KYJDAVBVYZEVOJ-UHFFFAOYSA-N 0.000 claims description 2
- YEPPKVMEYRBWMU-UHFFFAOYSA-N 5-[4-fluoro-2-(4-iodo-2-methylanilino)phenyl]-1,2-thiazol-3-one Chemical group CC1=CC(I)=CC=C1NC1=CC(F)=CC=C1C1=CC(O)=NS1 YEPPKVMEYRBWMU-UHFFFAOYSA-N 0.000 claims description 2
- TZQHVGWTHYZJOI-UHFFFAOYSA-N 5-[4-fluoro-2-(4-iodo-2-methylanilino)phenyl]-1,3,4-thiadiazol-2-amine Chemical group CC1=CC(I)=CC=C1NC1=CC(F)=CC=C1C1=NN=C(N)S1 TZQHVGWTHYZJOI-UHFFFAOYSA-N 0.000 claims description 2
- GVKKGNFBGDOOCY-UHFFFAOYSA-N 5-[4-fluoro-2-(4-iodo-2-methylanilino)phenyl]-3h-1,3,4-oxadiazole-2-thione Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=CC=C1C1=NN=C(S)O1 GVKKGNFBGDOOCY-UHFFFAOYSA-N 0.000 claims description 2
- TWCKPKFJGMRVNZ-UHFFFAOYSA-N 5-[4-fluoro-2-(4-iodo-2-methylanilino)phenyl]-3h-1,3,4-thiadiazol-2-one Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=CC=C1C1=NN=C(O)S1 TWCKPKFJGMRVNZ-UHFFFAOYSA-N 0.000 claims description 2
- HXERUZYXWJSQFS-UHFFFAOYSA-N 5-[4-fluoro-2-(4-iodo-2-methylanilino)phenyl]-3h-1,3,4-thiadiazole-2-thione Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=CC=C1C1=NN=C(S)S1 HXERUZYXWJSQFS-UHFFFAOYSA-N 0.000 claims description 2
- QMZIHEDWFZAVQG-UHFFFAOYSA-N 5-[5-bromo-3,4-difluoro-2-(4-iodo-2-methylanilino)phenyl]-1,2-dihydropyrazol-3-one Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=C(Br)C=C1C1=CC(O)=NN1 QMZIHEDWFZAVQG-UHFFFAOYSA-N 0.000 claims description 2
- UZQAKKCETQXWTR-UHFFFAOYSA-N 5-[5-bromo-3,4-difluoro-2-(4-iodo-2-methylanilino)phenyl]-1,2-oxazol-3-one Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=C(Br)C=C1C1=CC(O)=NO1 UZQAKKCETQXWTR-UHFFFAOYSA-N 0.000 claims description 2
- DMJSTYIZGPMWRM-UHFFFAOYSA-N 5-[5-bromo-3,4-difluoro-2-(4-iodo-2-methylanilino)phenyl]-1,2-thiazol-3-one Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=C(Br)C=C1C1=CC(O)=NS1 DMJSTYIZGPMWRM-UHFFFAOYSA-N 0.000 claims description 2
- FUBNEWYUVDXSEW-UHFFFAOYSA-N 5-[5-bromo-3,4-difluoro-2-(4-iodo-2-methylanilino)phenyl]-3h-1,3,4-oxadiazole-2-thione Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=C(Br)C=C1C1=NN=C(S)O1 FUBNEWYUVDXSEW-UHFFFAOYSA-N 0.000 claims description 2
- HDNIRQUOIOKKRS-UHFFFAOYSA-N 5-[5-bromo-3,4-difluoro-2-(4-iodo-2-methylanilino)phenyl]-3h-1,3,4-thiadiazol-2-one Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=C(Br)C=C1C1=NN=C(O)S1 HDNIRQUOIOKKRS-UHFFFAOYSA-N 0.000 claims description 2
- WCOVGMYPWHYONR-UHFFFAOYSA-N 5-[5-bromo-3,4-difluoro-2-(4-iodo-2-methylanilino)phenyl]-3h-1,3,4-thiadiazole-2-thione Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=C(Br)C=C1C1=NN=C(S)S1 WCOVGMYPWHYONR-UHFFFAOYSA-N 0.000 claims description 2
- UAHQCZNAVYTCSC-UHFFFAOYSA-N 5-fluoro-n-(4-iodo-2-methylphenyl)-2-(2h-tetrazol-5-yl)aniline Chemical group CC1=CC(I)=CC=C1NC1=CC(F)=CC=C1C1=NN=NN1 UAHQCZNAVYTCSC-UHFFFAOYSA-N 0.000 claims description 2
- IKCKSPFZYKIPEC-UHFFFAOYSA-N 5-fluoro-n-(4-iodo-2-methylphenyl)-4-nitro-2-(2h-tetrazol-5-yl)aniline Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=C([N+]([O-])=O)C=C1C1=NN=NN1 IKCKSPFZYKIPEC-UHFFFAOYSA-N 0.000 claims description 2
- 208000006820 Arthralgia Diseases 0.000 claims description 2
- IDRQGPFVPKEVPH-UHFFFAOYSA-N CC1=C(C=CC(=C1)I)NC2=CC(=C(C=C2N3C=CN=N3)[N+](=O)[O-])F Chemical compound CC1=C(C=CC(=C1)I)NC2=CC(=C(C=C2N3C=CN=N3)[N+](=O)[O-])F IDRQGPFVPKEVPH-UHFFFAOYSA-N 0.000 claims description 2
- IVEQTMOSBYJXPN-UHFFFAOYSA-N CC1=CC(I)=CC=C1NC1=C(F)C(F)=C(Br)C=C1C1=C(O)N(C)N=C1 Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=C(Br)C=C1C1=C(O)N(C)N=C1 IVEQTMOSBYJXPN-UHFFFAOYSA-N 0.000 claims description 2
- PYGOPEBHZKRETO-UHFFFAOYSA-N CC1=CC(I)=CC=C1NC1=C(F)C(F)=C(F)C=C1C1=C(O)N(C)N=C1 Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=C(F)C=C1C1=C(O)N(C)N=C1 PYGOPEBHZKRETO-UHFFFAOYSA-N 0.000 claims description 2
- BKIZNXZPDHMPNB-UHFFFAOYSA-N CC1=CC(I)=CC=C1NC1=C(F)C(F)=CC=C1C1=C(O)N(C)N=C1 Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=CC=C1C1=C(O)N(C)N=C1 BKIZNXZPDHMPNB-UHFFFAOYSA-N 0.000 claims description 2
- UFBFRYDHHVTGJS-UHFFFAOYSA-N CC1=CC(I)=CC=C1NC1=CC(F)=C([N+]([O-])=O)C=C1C1=C(O)N(C)N=C1 Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=C([N+]([O-])=O)C=C1C1=C(O)N(C)N=C1 UFBFRYDHHVTGJS-UHFFFAOYSA-N 0.000 claims description 2
- SZGAZIXGPNGOJI-UHFFFAOYSA-N CC1=CC(I)=CC=C1NC1=CC(F)=CC=C1C1=C(O)N(C)N=C1 Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=CC=C1C1=C(O)N(C)N=C1 SZGAZIXGPNGOJI-UHFFFAOYSA-N 0.000 claims description 2
- 208000025962 Crush injury Diseases 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 2
- 208000028389 Nerve injury Diseases 0.000 claims description 2
- 208000005890 Neuroma Diseases 0.000 claims description 2
- 208000004983 Phantom Limb Diseases 0.000 claims description 2
- 206010056238 Phantom pain Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 230000008764 nerve damage Effects 0.000 claims description 2
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims description 2
- 125000003944 tolyl group Chemical group 0.000 claims description 2
- 206010001605 Alcohol poisoning Diseases 0.000 claims 2
- QGXBMQOSLXTQHV-UHFFFAOYSA-N CC(C=C(C=C1)I)=C1NC(C=C(C([N+]([O-])=O)=C1)F)=C1C1=NN=CN1 Chemical compound CC(C=C(C=C1)I)=C1NC(C=C(C([N+]([O-])=O)=C1)F)=C1C1=NN=CN1 QGXBMQOSLXTQHV-UHFFFAOYSA-N 0.000 claims 2
- APKZPKINPXTSNL-UHFFFAOYSA-N 1,3,4-oxadiazol-2-amine Chemical compound NC1=NN=CO1 APKZPKINPXTSNL-UHFFFAOYSA-N 0.000 claims 1
- 125000005266 diarylamine group Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 description 44
- 238000003786 synthesis reaction Methods 0.000 description 44
- 241001465754 Metazoa Species 0.000 description 38
- UHAXDAKQGVISBZ-UHFFFAOYSA-N N-(cyclopropylmethoxy)-3,4,5-trifluoro-2-(4-iodo-2-methylanilino)benzamide Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=C(F)C=C1C(=O)NOCC1CC1 UHAXDAKQGVISBZ-UHFFFAOYSA-N 0.000 description 35
- 230000003068 static effect Effects 0.000 description 33
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 29
- 230000000694 effects Effects 0.000 description 28
- 229960001233 pregabalin Drugs 0.000 description 28
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 17
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 17
- 239000003981 vehicle Substances 0.000 description 17
- 230000000638 stimulation Effects 0.000 description 16
- 241000700159 Rattus Species 0.000 description 15
- 210000002683 foot Anatomy 0.000 description 15
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 15
- 229960001052 streptozocin Drugs 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- 108091054455 MAP kinase family Proteins 0.000 description 12
- 102000043136 MAP kinase family Human genes 0.000 description 12
- 230000007794 irritation Effects 0.000 description 12
- 150000001408 amides Chemical class 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 229940124530 sulfonamide Drugs 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 10
- 238000000354 decomposition reaction Methods 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 238000002844 melting Methods 0.000 description 10
- 230000008018 melting Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- GFMMXOIFOQCCGU-UHFFFAOYSA-N 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide Chemical compound C=1C=C(I)C=C(Cl)C=1NC1=C(F)C(F)=CC=C1C(=O)NOCC1CC1 GFMMXOIFOQCCGU-UHFFFAOYSA-N 0.000 description 8
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- 108091000080 Phosphotransferase Proteins 0.000 description 8
- 235000019439 ethyl acetate Nutrition 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 102000020233 phosphotransferase Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 102000016914 ras Proteins Human genes 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 208000026935 allergic disease Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 6
- 230000000622 irritating effect Effects 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 5
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 5
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 5
- 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000009610 hypersensitivity Effects 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical class CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 101710146529 Dual specificity mitogen-activated protein kinase kinase 2 Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 4
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 102000001253 Protein Kinase Human genes 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 125000004093 cyano group Chemical group *C#N 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 150000004702 methyl esters Chemical class 0.000 description 4
- 230000002981 neuropathic effect Effects 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 108060006633 protein kinase Proteins 0.000 description 4
- 210000003497 sciatic nerve Anatomy 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 4
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 150000000185 1,3-diols Chemical class 0.000 description 3
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 3
- XRNCNLRJMNWXRG-UHFFFAOYSA-N 3,4-difluoro-2-(4-iodo-2-methylanilino)benzoic acid Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=CC=C1C(O)=O XRNCNLRJMNWXRG-UHFFFAOYSA-N 0.000 description 3
- SPISVAXWLMYMPW-UHFFFAOYSA-N 5-[7-fluoro-6-(4-iodo-2-methylanilino)-1,3-benzothiazol-5-yl]-3h-1,3,4-oxadiazol-2-one Chemical compound CC1=CC(I)=CC=C1NC(C(=C1)C=2OC(O)=NN=2)=C(F)C2=C1N=CS2 SPISVAXWLMYMPW-UHFFFAOYSA-N 0.000 description 3
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 3
- 208000004454 Hyperalgesia Diseases 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000004103 aminoalkyl group Chemical group 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical class C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 3
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 150000002081 enamines Chemical class 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 125000005027 hydroxyaryl group Chemical group 0.000 description 3
- 150000002466 imines Chemical class 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000007913 intrathecal administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 3
- 229940058020 2-amino-2-methyl-1-propanol Drugs 0.000 description 2
- SSOPDSFJWPZZBT-UHFFFAOYSA-N 2-fluoro-4-(4-iodoanilino)-5-(5-oxo-1,2-dihydrotriazol-4-yl)benzenesulfonamide Chemical compound C=1C=C(I)C=CC=1NC=1C=C(F)C(S(=O)(=O)N)=CC=1C=1NN=NC=1O SSOPDSFJWPZZBT-UHFFFAOYSA-N 0.000 description 2
- FLWVAHBGRKYNEE-UHFFFAOYSA-N 2-sulfanyl-3h-oxadiazole Chemical compound SN1NC=CO1 FLWVAHBGRKYNEE-UHFFFAOYSA-N 0.000 description 2
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 2
- OQPPWRYNXRWUAQ-UHFFFAOYSA-N 3-hydroxybenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC(O)=C1 OQPPWRYNXRWUAQ-UHFFFAOYSA-N 0.000 description 2
- RUBRCWOFANAOTP-UHFFFAOYSA-N 3h-1,3,4-oxadiazole-2-thione Chemical compound S=C1NN=CO1 RUBRCWOFANAOTP-UHFFFAOYSA-N 0.000 description 2
- BJCLIGQKOOTBLG-UHFFFAOYSA-N 4-(3-amino-1,2-oxazol-4-yl)-2-chloro-5-(4-iodoanilino)benzenesulfonamide Chemical compound NC1=NOC=C1C1=CC(Cl)=C(S(N)(=O)=O)C=C1NC1=CC=C(I)C=C1 BJCLIGQKOOTBLG-UHFFFAOYSA-N 0.000 description 2
- JOOXCMJARBKPKM-UHFFFAOYSA-M 4-oxopentanoate Chemical compound CC(=O)CCC([O-])=O JOOXCMJARBKPKM-UHFFFAOYSA-M 0.000 description 2
- CLXZLZYPOYXMNR-UHFFFAOYSA-N 5-(3-amino-1,2-oxazol-4-yl)-2,3-difluoro-4-(4-iodo-2-methylanilino)benzenesulfonamide Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=C(S(N)(=O)=O)C=C1C1=CON=C1N CLXZLZYPOYXMNR-UHFFFAOYSA-N 0.000 description 2
- NUFKAMDSONFFPJ-UHFFFAOYSA-N 5-(3-amino-1,2-oxazol-4-yl)-2-fluoro-4-(4-iodo-2-methylanilino)benzenesulfonamide Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=C(S(N)(=O)=O)C=C1C1=CON=C1N NUFKAMDSONFFPJ-UHFFFAOYSA-N 0.000 description 2
- CZFXBOHIVLASGN-UHFFFAOYSA-N 5-(3-amino-1,2-oxazol-4-yl)-2-fluoro-4-(4-iodoanilino)benzenesulfonamide Chemical compound NC1=NOC=C1C1=CC(S(N)(=O)=O)=C(F)C=C1NC1=CC=C(I)C=C1 CZFXBOHIVLASGN-UHFFFAOYSA-N 0.000 description 2
- CKQFDRMKSBKNTR-UHFFFAOYSA-N 5-(3-amino-1,2-oxazol-4-yl)-4-(2-chloro-4-iodoanilino)-2,3-difluorobenzenesulfonamide Chemical compound NC1=NOC=C1C1=CC(S(N)(=O)=O)=C(F)C(F)=C1NC1=CC=C(I)C=C1Cl CKQFDRMKSBKNTR-UHFFFAOYSA-N 0.000 description 2
- WJOGFGRGXNRPHD-UHFFFAOYSA-N 5-(3-amino-1,2-oxazol-4-yl)-4-(2-chloro-4-iodoanilino)-2-fluorobenzenesulfonamide Chemical compound NC1=NOC=C1C1=CC(S(N)(=O)=O)=C(F)C=C1NC1=CC=C(I)C=C1Cl WJOGFGRGXNRPHD-UHFFFAOYSA-N 0.000 description 2
- XFEZJJWXJXULKK-UHFFFAOYSA-N 5-(5-amino-1,3,4-oxadiazol-2-yl)-2-fluoro-4-(4-iodo-2-methylanilino)benzenesulfonamide Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=C(S(N)(=O)=O)C=C1C1=NN=C(N)O1 XFEZJJWXJXULKK-UHFFFAOYSA-N 0.000 description 2
- XUQVCLMHTYBOHW-UHFFFAOYSA-N 5-(5-amino-1,3,4-oxadiazol-2-yl)-2-fluoro-4-(4-iodoanilino)benzenesulfonamide Chemical compound O1C(N)=NN=C1C1=CC(S(N)(=O)=O)=C(F)C=C1NC1=CC=C(I)C=C1 XUQVCLMHTYBOHW-UHFFFAOYSA-N 0.000 description 2
- ICCNMOGERNHRMJ-UHFFFAOYSA-N 5-[2-amino-6-(4-iodo-2-methylanilino)-1,3-benzothiazol-5-yl]-3h-1,3,4-oxadiazol-2-one Chemical compound CC1=CC(I)=CC=C1NC(C(=C1)C=2OC(O)=NN=2)=CC2=C1N=C(N)S2 ICCNMOGERNHRMJ-UHFFFAOYSA-N 0.000 description 2
- RREYEFABQUPQLC-UHFFFAOYSA-N 5-[5-(2-chloro-4-iodoanilino)-1h-indazol-6-yl]-3h-1,3,4-oxadiazol-2-one Chemical compound O1C(O)=NN=C1C(C(=C1)NC=2C(=CC(I)=CC=2)Cl)=CC2=C1C=NN2 RREYEFABQUPQLC-UHFFFAOYSA-N 0.000 description 2
- RLOSTTAMNOJPRH-UHFFFAOYSA-N 5-[6-(4-iodoanilino)-1h-indol-5-yl]-3h-1,3,4-oxadiazol-2-one Chemical compound O1C(O)=NN=C1C(C(=C1)NC=2C=CC(I)=CC=2)=CC2=C1NC=C2 RLOSTTAMNOJPRH-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical class COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 208000035154 Hyperesthesia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 2
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 2
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 229940022663 acetate Drugs 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000005001 aminoaryl group Chemical group 0.000 description 2
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 210000001742 aqueous humor Anatomy 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 125000003709 fluoroalkyl group Chemical group 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- BRWIZMBXBAOCCF-UHFFFAOYSA-N hydrazinecarbothioamide Chemical compound NNC(N)=S BRWIZMBXBAOCCF-UHFFFAOYSA-N 0.000 description 2
- 125000005020 hydroxyalkenyl group Chemical group 0.000 description 2
- 125000005016 hydroxyalkynyl group Chemical group 0.000 description 2
- 125000005350 hydroxycycloalkyl group Chemical group 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 201000005518 mononeuropathy Diseases 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000012457 nonaqueous media Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000005493 quinolyl group Chemical group 0.000 description 2
- 238000013102 re-test Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 125000003638 stannyl group Chemical group [H][Sn]([H])([H])* 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 150000003871 sulfonates Chemical class 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- SODPIMGUZLOIPE-UHFFFAOYSA-N (4-chlorophenoxy)acetic acid Chemical compound OC(=O)COC1=CC=C(Cl)C=C1 SODPIMGUZLOIPE-UHFFFAOYSA-N 0.000 description 1
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 description 1
- YDVARACJVYZWSP-UHFFFAOYSA-N 1,2-oxazole-3-thione Chemical compound SC=1C=CON=1 YDVARACJVYZWSP-UHFFFAOYSA-N 0.000 description 1
- ILWJAOPQHOZXAN-UHFFFAOYSA-N 1,3-dithianyl Chemical group [CH]1SCCCS1 ILWJAOPQHOZXAN-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- COSIAPCCAMTTOC-UHFFFAOYSA-N 2,3-difluoro-4-(4-iodo-2-methylanilino)-5-(3-oxo-1,2-dihydropyrazol-4-yl)benzenesulfonamide Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=C(S(N)(=O)=O)C=C1C1=C(O)NN=C1 COSIAPCCAMTTOC-UHFFFAOYSA-N 0.000 description 1
- IRFSWSCOSQQPDV-UHFFFAOYSA-N 2,3-difluoro-4-(4-iodo-2-methylanilino)-5-(3-oxo-1,2-oxazol-5-yl)benzenesulfonamide Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=C(S(N)(=O)=O)C=C1C1=CC(O)=NO1 IRFSWSCOSQQPDV-UHFFFAOYSA-N 0.000 description 1
- MRYJJSOLQZIMGB-UHFFFAOYSA-N 2,3-difluoro-4-(4-iodo-2-methylanilino)-5-(3-sulfanylidene-1,2-oxazol-5-yl)benzenesulfonamide Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=C(S(N)(=O)=O)C=C1C1=CC(S)=NO1 MRYJJSOLQZIMGB-UHFFFAOYSA-N 0.000 description 1
- FFFIRKXTFQCCKJ-UHFFFAOYSA-M 2,4,6-trimethylbenzoate Chemical compound CC1=CC(C)=C(C([O-])=O)C(C)=C1 FFFIRKXTFQCCKJ-UHFFFAOYSA-M 0.000 description 1
- OVOJUAKDTOOXRF-UHFFFAOYSA-N 2,4-dinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O OVOJUAKDTOOXRF-UHFFFAOYSA-N 0.000 description 1
- NHZLLKNRTDIFAD-UHFFFAOYSA-N 2,5-dihydro-1,3-oxazole Chemical compound C1OCN=C1 NHZLLKNRTDIFAD-UHFFFAOYSA-N 0.000 description 1
- PGWWLXYWCNLJKL-UHFFFAOYSA-N 2,6-difluoro-3-(4-iodoanilino)-4-(5-oxo-2h-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound C=1C=C(I)C=CC=1NC1=C(F)C(S(=O)(=O)N)=C(F)C=C1C1=CC(=O)ON1 PGWWLXYWCNLJKL-UHFFFAOYSA-N 0.000 description 1
- DQOWKFWPCYWWEW-UHFFFAOYSA-N 2,6-difluoro-3-(4-iodoanilino)-4-(5-oxo-2h-tetrazol-1-yl)benzenesulfonamide Chemical compound FC=1C(S(=O)(=O)N)=C(F)C=C(N2C(NN=N2)=O)C=1NC1=CC=C(I)C=C1 DQOWKFWPCYWWEW-UHFFFAOYSA-N 0.000 description 1
- YURLCYGZYWDCHL-UHFFFAOYSA-N 2-(2,6-dichloro-4-methylphenoxy)acetic acid Chemical compound CC1=CC(Cl)=C(OCC(O)=O)C(Cl)=C1 YURLCYGZYWDCHL-UHFFFAOYSA-N 0.000 description 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- WOXFMYVTSLAQMO-UHFFFAOYSA-N 2-Pyridinemethanamine Chemical compound NCC1=CC=CC=N1 WOXFMYVTSLAQMO-UHFFFAOYSA-N 0.000 description 1
- PVWNGZOPGGKNSI-UHFFFAOYSA-N 2-bromo-5-(4-iodoanilino)-4-(3-oxo-1,2-oxazol-4-yl)benzenesulfonamide Chemical compound C=1ON=C(O)C=1C=1C=C(Br)C(S(=O)(=O)N)=CC=1NC1=CC=C(I)C=C1 PVWNGZOPGGKNSI-UHFFFAOYSA-N 0.000 description 1
- QKSGIGXOKHZCQZ-UHFFFAOYSA-N 2-chloro-2-phenylacetic acid Chemical compound OC(=O)C(Cl)C1=CC=CC=C1 QKSGIGXOKHZCQZ-UHFFFAOYSA-N 0.000 description 1
- AMIWCBRLDFWNAV-UHFFFAOYSA-N 2-fluoro-4-(4-iodo-2-methylanilino)-5-(3-oxo-1,2-oxazol-4-yl)benzenesulfonamide Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=C(S(N)(=O)=O)C=C1C1=CON=C1O AMIWCBRLDFWNAV-UHFFFAOYSA-N 0.000 description 1
- FLCRCXXXMQMXDG-UHFFFAOYSA-N 2-fluoro-4-(4-iodo-2-methylanilino)-5-(3-oxo-1,2-oxazol-5-yl)benzenesulfonamide Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=C(S(N)(=O)=O)C=C1C1=CC(O)=NO1 FLCRCXXXMQMXDG-UHFFFAOYSA-N 0.000 description 1
- MLWKEZZITLRYAM-UHFFFAOYSA-N 2-fluoro-4-(4-iodo-2-methylanilino)-5-(3-sulfanylidene-1,2-oxazol-5-yl)benzenesulfonamide Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=C(S(N)(=O)=O)C=C1C1=CC(S)=NO1 MLWKEZZITLRYAM-UHFFFAOYSA-N 0.000 description 1
- HAGZBZRGHCVPNV-UHFFFAOYSA-N 2-fluoro-4-(4-iodo-2-methylanilino)-5-(5-oxo-2h-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=C(S(N)(=O)=O)C=C1C1=CC(=O)ON1 HAGZBZRGHCVPNV-UHFFFAOYSA-N 0.000 description 1
- HQHNYELVXOBVAM-UHFFFAOYSA-N 2-fluoro-4-(4-iodo-2-methylanilino)-5-(5-oxo-2h-tetrazol-1-yl)benzenesulfonamide Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=C(S(N)(=O)=O)C=C1N1C(=O)NN=N1 HQHNYELVXOBVAM-UHFFFAOYSA-N 0.000 description 1
- JQZPDRQNZTYSKP-UHFFFAOYSA-N 2-fluoro-4-(4-iodoanilino)-5-(2-oxo-3h-1,3,4-thiadiazol-5-yl)benzenesulfonamide Chemical compound C=1C=C(I)C=CC=1NC=1C=C(F)C(S(=O)(=O)N)=CC=1C1=NN=C(O)S1 JQZPDRQNZTYSKP-UHFFFAOYSA-N 0.000 description 1
- DAAVIGSCMRQPEN-UHFFFAOYSA-N 2-fluoro-4-(4-iodoanilino)-5-(2-sulfanylidene-3h-1,3,4-oxadiazol-5-yl)benzenesulfonamide Chemical compound C=1C=C(I)C=CC=1NC=1C=C(F)C(S(=O)(=O)N)=CC=1C1=NN=C(S)O1 DAAVIGSCMRQPEN-UHFFFAOYSA-N 0.000 description 1
- JGNJGMKYZFRBTL-UHFFFAOYSA-N 2-fluoro-4-(4-iodoanilino)-5-(3-oxo-1,2-oxazol-4-yl)benzenesulfonamide Chemical compound C=1C=C(I)C=CC=1NC=1C=C(F)C(S(=O)(=O)N)=CC=1C1=CON=C1O JGNJGMKYZFRBTL-UHFFFAOYSA-N 0.000 description 1
- WQLSYJYGMOKMFW-UHFFFAOYSA-N 2-fluoro-4-(4-iodoanilino)-5-(3-oxo-1,2-oxazol-5-yl)benzenesulfonamide Chemical compound C=1C=C(I)C=CC=1NC=1C=C(F)C(S(=O)(=O)N)=CC=1C1=CC(O)=NO1 WQLSYJYGMOKMFW-UHFFFAOYSA-N 0.000 description 1
- NLWSEUJOGQECSD-UHFFFAOYSA-N 2-fluoro-4-(4-iodoanilino)-5-(3-sulfanylidene-1,2-oxazol-5-yl)benzenesulfonamide Chemical compound C=1C=C(I)C=CC=1NC=1C=C(F)C(S(=O)(=O)N)=CC=1C1=CC(S)=NO1 NLWSEUJOGQECSD-UHFFFAOYSA-N 0.000 description 1
- HGMRGOTWIXPGLE-UHFFFAOYSA-N 2-fluoro-4-(4-iodoanilino)-5-(5-oxo-2h-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound C=1C=C(I)C=CC=1NC=1C=C(F)C(S(=O)(=O)N)=CC=1C1=CC(=O)ON1 HGMRGOTWIXPGLE-UHFFFAOYSA-N 0.000 description 1
- RPJAEFVTEJVTQI-UHFFFAOYSA-N 2-fluoro-4-(4-iodoanilino)-5-(5-oxo-2h-tetrazol-1-yl)benzenesulfonamide Chemical compound C1=C(F)C(S(=O)(=O)N)=CC(N2C(NN=N2)=O)=C1NC1=CC=C(I)C=C1 RPJAEFVTEJVTQI-UHFFFAOYSA-N 0.000 description 1
- PNUBZMMVMPTWCY-UHFFFAOYSA-N 2-fluoro-5-(4-iodoanilino)-4-(2-oxo-3h-1,3,4-thiadiazol-5-yl)benzenesulfonamide Chemical compound N=1N=C(O)SC=1C=1C=C(F)C(S(=O)(=O)N)=CC=1NC1=CC=C(I)C=C1 PNUBZMMVMPTWCY-UHFFFAOYSA-N 0.000 description 1
- PHSGXYOGKSQNAX-UHFFFAOYSA-N 2-fluoro-5-(4-iodoanilino)-4-(2-sulfanylidene-3h-1,3,4-oxadiazol-5-yl)benzenesulfonamide Chemical compound N=1N=C(S)OC=1C=1C=C(F)C(S(=O)(=O)N)=CC=1NC1=CC=C(I)C=C1 PHSGXYOGKSQNAX-UHFFFAOYSA-N 0.000 description 1
- PHEOHTLQTIABPX-UHFFFAOYSA-N 2-fluoro-5-(4-iodoanilino)-4-(3-oxo-1,2-dihydropyrazol-4-yl)benzenesulfonamide Chemical compound C1=NNC(O)=C1C=1C=C(F)C(S(=O)(=O)N)=CC=1NC1=CC=C(I)C=C1 PHEOHTLQTIABPX-UHFFFAOYSA-N 0.000 description 1
- BWKWGTFKPVVNTL-UHFFFAOYSA-N 2-fluoro-5-(4-iodoanilino)-4-(3-oxo-1,2-oxazol-5-yl)benzenesulfonamide Chemical compound C=1C(O)=NOC=1C=1C=C(F)C(S(=O)(=O)N)=CC=1NC1=CC=C(I)C=C1 BWKWGTFKPVVNTL-UHFFFAOYSA-N 0.000 description 1
- BZBSHWOOZKHOHS-UHFFFAOYSA-N 2-fluoro-5-(4-iodoanilino)-4-(4-methyl-5-oxotetrazol-1-yl)benzenesulfonamide Chemical compound O=C1N(C)N=NN1C1=CC(F)=C(S(N)(=O)=O)C=C1NC1=CC=C(I)C=C1 BZBSHWOOZKHOHS-UHFFFAOYSA-N 0.000 description 1
- FFGKFOKXDKXIJR-UHFFFAOYSA-N 2-fluoro-5-(4-iodoanilino)-4-(5-oxo-1,2-dihydro-1,2,4-triazol-3-yl)benzenesulfonamide Chemical compound N=1N=C(O)NC=1C=1C=C(F)C(S(=O)(=O)N)=CC=1NC1=CC=C(I)C=C1 FFGKFOKXDKXIJR-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- CJNZAXGUTKBIHP-UHFFFAOYSA-M 2-iodobenzoate Chemical compound [O-]C(=O)C1=CC=CC=C1I CJNZAXGUTKBIHP-UHFFFAOYSA-M 0.000 description 1
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- GPVOTFQILZVCFP-UHFFFAOYSA-N 2-trityloxyacetic acid Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCC(=O)O)C1=CC=CC=C1 GPVOTFQILZVCFP-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- OVZHELCFKSFINS-UHFFFAOYSA-N 3h-1,3,4-thiadiazol-2-one Chemical compound O=C1NN=CS1 OVZHELCFKSFINS-UHFFFAOYSA-N 0.000 description 1
- UBARRNXCKBFUEN-UHFFFAOYSA-N 4,5-diphenyl-5h-1,3-oxazol-2-one Chemical compound N=1C(=O)OC(C=2C=CC=CC=2)C=1C1=CC=CC=C1 UBARRNXCKBFUEN-UHFFFAOYSA-N 0.000 description 1
- ZJXODJRQLVZIRO-UHFFFAOYSA-N 4-(2-chloro-4-iodoanilino)-2,3-difluoro-5-(3-oxo-1,2-dihydropyrazol-4-yl)benzenesulfonamide Chemical compound C=1C=C(I)C=C(Cl)C=1NC=1C(F)=C(F)C(S(=O)(=O)N)=CC=1C=1C=NNC=1O ZJXODJRQLVZIRO-UHFFFAOYSA-N 0.000 description 1
- LBHNNLBZMDIAGO-UHFFFAOYSA-N 4-(2-chloro-4-iodoanilino)-2,3-difluoro-5-(3-oxo-1,2-oxazol-4-yl)benzenesulfonamide Chemical compound C=1C=C(I)C=C(Cl)C=1NC=1C(F)=C(F)C(S(=O)(=O)N)=CC=1C1=CON=C1O LBHNNLBZMDIAGO-UHFFFAOYSA-N 0.000 description 1
- FMNIGWQOOJMFCQ-UHFFFAOYSA-N 4-(2-chloro-4-iodoanilino)-2,3-difluoro-5-(3-oxo-1,2-oxazol-5-yl)benzenesulfonamide Chemical compound C=1C=C(I)C=C(Cl)C=1NC=1C(F)=C(F)C(S(=O)(=O)N)=CC=1C1=CC(O)=NO1 FMNIGWQOOJMFCQ-UHFFFAOYSA-N 0.000 description 1
- SNFHMDDAQGKESP-UHFFFAOYSA-N 4-(2-chloro-4-iodoanilino)-2,3-difluoro-5-(3-sulfanylidene-1,2-oxazol-5-yl)benzenesulfonamide Chemical compound C=1C=C(I)C=C(Cl)C=1NC=1C(F)=C(F)C(S(=O)(=O)N)=CC=1C1=CC(S)=NO1 SNFHMDDAQGKESP-UHFFFAOYSA-N 0.000 description 1
- UUWYWEHGYRNUSM-UHFFFAOYSA-N 4-(2-chloro-4-iodoanilino)-2-fluoro-5-(3-oxo-1,2-dihydropyrazol-4-yl)benzenesulfonamide Chemical compound C=1C=C(I)C=C(Cl)C=1NC=1C=C(F)C(S(=O)(=O)N)=CC=1C=1C=NNC=1O UUWYWEHGYRNUSM-UHFFFAOYSA-N 0.000 description 1
- HXKRRZJRVPQOHJ-UHFFFAOYSA-N 4-(2-chloro-4-iodoanilino)-2-fluoro-5-(3-oxo-1,2-oxazol-4-yl)benzenesulfonamide Chemical compound C=1C=C(I)C=C(Cl)C=1NC=1C=C(F)C(S(=O)(=O)N)=CC=1C1=CON=C1O HXKRRZJRVPQOHJ-UHFFFAOYSA-N 0.000 description 1
- GUCNUYLYYODQHE-UHFFFAOYSA-N 4-(2-chloro-4-iodoanilino)-2-fluoro-5-(3-oxo-1,2-oxazol-5-yl)benzenesulfonamide Chemical compound C=1C=C(I)C=C(Cl)C=1NC=1C=C(F)C(S(=O)(=O)N)=CC=1C1=CC(O)=NO1 GUCNUYLYYODQHE-UHFFFAOYSA-N 0.000 description 1
- UYGGCTXDKJSADJ-UHFFFAOYSA-N 4-(2-chloro-4-iodoanilino)-2-fluoro-5-(3-sulfanylidene-1,2-oxazol-5-yl)benzenesulfonamide Chemical compound C=1C=C(I)C=C(Cl)C=1NC=1C=C(F)C(S(=O)(=O)N)=CC=1C1=CC(S)=NO1 UYGGCTXDKJSADJ-UHFFFAOYSA-N 0.000 description 1
- BBFQSPCBHLXUKZ-UHFFFAOYSA-N 4-(2-chloro-4-iodoanilino)-2-fluoro-5-(5-oxo-2h-tetrazol-1-yl)benzenesulfonamide Chemical compound C1=C(F)C(S(=O)(=O)N)=CC(N2C(NN=N2)=O)=C1NC1=CC=C(I)C=C1Cl BBFQSPCBHLXUKZ-UHFFFAOYSA-N 0.000 description 1
- WGMNYEIKCIBKKL-UHFFFAOYSA-N 4-(3-amino-1,2-oxazol-5-yl)-2-bromo-5-(4-iodoanilino)benzenesulfonamide Chemical compound O1N=C(N)C=C1C1=CC(Br)=C(S(N)(=O)=O)C=C1NC1=CC=C(I)C=C1 WGMNYEIKCIBKKL-UHFFFAOYSA-N 0.000 description 1
- CBSPMBCEUUUOMQ-UHFFFAOYSA-N 4-(3-amino-1h-1,2,4-triazol-5-yl)-2-fluoro-5-(4-iodoanilino)benzenesulfonamide Chemical compound N1C(N)=NN=C1C1=CC(F)=C(S(N)(=O)=O)C=C1NC1=CC=C(I)C=C1 CBSPMBCEUUUOMQ-UHFFFAOYSA-N 0.000 description 1
- QMQRAEVRXDEHQH-UHFFFAOYSA-N 4-(5-amino-1,3,4-oxadiazol-2-yl)-2-fluoro-5-(4-iodoanilino)benzenesulfonamide Chemical compound O1C(N)=NN=C1C1=CC(F)=C(S(N)(=O)=O)C=C1NC1=CC=C(I)C=C1 QMQRAEVRXDEHQH-UHFFFAOYSA-N 0.000 description 1
- NBRHFLGKEMIMAB-UHFFFAOYSA-N 4-(5-amino-1,3,4-thiadiazol-2-yl)-5-(4-iodoanilino)-2-sulfanylbenzenesulfonamide Chemical compound S1C(N)=NN=C1C1=CC(S)=C(S(N)(=O)=O)C=C1NC1=CC=C(I)C=C1 NBRHFLGKEMIMAB-UHFFFAOYSA-N 0.000 description 1
- HNEPRUSQLALWQX-UHFFFAOYSA-N 4-(5-amino-2h-pyrrol-4-yl)-2-chloro-5-(4-iodoanilino)benzenesulfonamide Chemical compound NC1=NCC=C1C1=CC(Cl)=C(S(N)(=O)=O)C=C1NC1=CC=C(I)C=C1 HNEPRUSQLALWQX-UHFFFAOYSA-N 0.000 description 1
- BAKYASSDAXQKKY-UHFFFAOYSA-N 4-Hydroxy-3-methylbenzaldehyde Chemical compound CC1=CC(C=O)=CC=C1O BAKYASSDAXQKKY-UHFFFAOYSA-N 0.000 description 1
- YZEHYLDQCQSQOE-UHFFFAOYSA-N 4-[4-fluoro-2-(4-iodo-2-methylanilino)-5-nitrophenyl]-2-methyl-1h-pyrazol-5-one Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=C([N+]([O-])=O)C=C1C1=CN(C)N=C1O YZEHYLDQCQSQOE-UHFFFAOYSA-N 0.000 description 1
- JSPJSYCERHKJBF-UHFFFAOYSA-N 4-[4-fluoro-2-(4-iodo-2-methylanilino)-5-nitrophenyl]-4h-1,2-oxazol-5-one Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=C([N+]([O-])=O)C=C1C1C(=O)ON=C1 JSPJSYCERHKJBF-UHFFFAOYSA-N 0.000 description 1
- WAGMYTXJRVPMGW-UHFFFAOYSA-N 4-azidobutanoic acid Chemical compound OC(=O)CCCN=[N+]=[N-] WAGMYTXJRVPMGW-UHFFFAOYSA-N 0.000 description 1
- 125000006281 4-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Br)C([H])([H])* 0.000 description 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
- BGKLFAQCHHCZRZ-UHFFFAOYSA-N 4-iodo-2-methylaniline Chemical compound CC1=CC(I)=CC=C1N BGKLFAQCHHCZRZ-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- NNJMFJSKMRYHSR-UHFFFAOYSA-M 4-phenylbenzoate Chemical compound C1=CC(C(=O)[O-])=CC=C1C1=CC=CC=C1 NNJMFJSKMRYHSR-UHFFFAOYSA-M 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- AOSLGLAFPKSSNJ-UHFFFAOYSA-N 5-(3-amino-1,2-oxazol-5-yl)-2,3-difluoro-4-(4-iodo-2-methylanilino)benzenesulfonamide Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=C(S(N)(=O)=O)C=C1C1=CC(N)=NO1 AOSLGLAFPKSSNJ-UHFFFAOYSA-N 0.000 description 1
- LPKDGXKZABZDGV-UHFFFAOYSA-N 5-(3-amino-1,2-oxazol-5-yl)-2-fluoro-4-(4-iodo-2-methylanilino)benzenesulfonamide Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=C(S(N)(=O)=O)C=C1C1=CC(N)=NO1 LPKDGXKZABZDGV-UHFFFAOYSA-N 0.000 description 1
- ODPIXSAKWJEDPM-UHFFFAOYSA-N 5-(3-amino-1,2-oxazol-5-yl)-2-fluoro-4-(4-iodoanilino)benzenesulfonamide Chemical compound O1N=C(N)C=C1C1=CC(S(N)(=O)=O)=C(F)C=C1NC1=CC=C(I)C=C1 ODPIXSAKWJEDPM-UHFFFAOYSA-N 0.000 description 1
- BOYZSHFZJSYNCB-UHFFFAOYSA-N 5-(3-amino-1,2-oxazol-5-yl)-4-(2-chloro-4-iodoanilino)-2,3-difluorobenzenesulfonamide Chemical compound O1N=C(N)C=C1C1=CC(S(N)(=O)=O)=C(F)C(F)=C1NC1=CC=C(I)C=C1Cl BOYZSHFZJSYNCB-UHFFFAOYSA-N 0.000 description 1
- OBQMBEKMEJBONF-UHFFFAOYSA-N 5-(3-amino-1,2-oxazol-5-yl)-4-(2-chloro-4-iodoanilino)-2-fluorobenzenesulfonamide Chemical compound O1N=C(N)C=C1C1=CC(S(N)(=O)=O)=C(F)C=C1NC1=CC=C(I)C=C1Cl OBQMBEKMEJBONF-UHFFFAOYSA-N 0.000 description 1
- APXYYAOIFFKDBI-UHFFFAOYSA-N 5-(5-amino-1,3,4-oxadiazol-2-yl)-4-(2-chloro-4-iodoanilino)-2,3-difluoro-n-[3-(4-methylpiperazin-1-yl)propyl]benzenesulfonamide Chemical compound C1CN(C)CCN1CCCNS(=O)(=O)C(C(=C1F)F)=CC(C=2OC(N)=NN=2)=C1NC1=CC=C(I)C=C1Cl APXYYAOIFFKDBI-UHFFFAOYSA-N 0.000 description 1
- YALWEHBJSHKOGV-UHFFFAOYSA-N 5-(5-amino-1,3,4-oxadiazol-2-yl)-4-(2-chloro-4-iodoanilino)-2-fluorobenzenesulfonamide Chemical compound O1C(N)=NN=C1C1=CC(S(N)(=O)=O)=C(F)C=C1NC1=CC=C(I)C=C1Cl YALWEHBJSHKOGV-UHFFFAOYSA-N 0.000 description 1
- VXVCRVJROPWWFM-UHFFFAOYSA-N 5-(5-amino-1,3,4-thiadiazol-2-yl)-2-fluoro-4-(4-iodo-2-methylanilino)benzenesulfonamide Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=C(S(N)(=O)=O)C=C1C1=NN=C(N)S1 VXVCRVJROPWWFM-UHFFFAOYSA-N 0.000 description 1
- LSZYSEUNWZMCQV-UHFFFAOYSA-N 5-(5-amino-1,3,4-thiadiazol-2-yl)-2-fluoro-4-(4-iodoanilino)benzenesulfonamide Chemical compound S1C(N)=NN=C1C1=CC(S(N)(=O)=O)=C(F)C=C1NC1=CC=C(I)C=C1 LSZYSEUNWZMCQV-UHFFFAOYSA-N 0.000 description 1
- JGGRHXGJJXYGOF-UHFFFAOYSA-N 5-(5-amino-2h-pyrrol-4-yl)-2,3-difluoro-4-(4-iodo-2-methylanilino)benzenesulfonamide Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=C(S(N)(=O)=O)C=C1C1=CCN=C1N JGGRHXGJJXYGOF-UHFFFAOYSA-N 0.000 description 1
- QIDQKPNYSZTINH-UHFFFAOYSA-N 5-(5-amino-2h-pyrrol-4-yl)-2-fluoro-4-(4-iodo-2-methylanilino)benzenesulfonamide Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=C(S(N)(=O)=O)C=C1C1=CCN=C1N QIDQKPNYSZTINH-UHFFFAOYSA-N 0.000 description 1
- YCUIWYUBANJYSV-UHFFFAOYSA-N 5-(5-amino-2h-pyrrol-4-yl)-2-fluoro-4-(4-iodoanilino)benzenesulfonamide Chemical compound NC1=NCC=C1C1=CC(S(N)(=O)=O)=C(F)C=C1NC1=CC=C(I)C=C1 YCUIWYUBANJYSV-UHFFFAOYSA-N 0.000 description 1
- LKXMWPXRWFCDDV-UHFFFAOYSA-N 5-(5-amino-2h-pyrrol-4-yl)-4-(2-chloro-4-iodoanilino)-2,3-difluorobenzenesulfonamide Chemical compound NC1=NCC=C1C1=CC(S(N)(=O)=O)=C(F)C(F)=C1NC1=CC=C(I)C=C1Cl LKXMWPXRWFCDDV-UHFFFAOYSA-N 0.000 description 1
- LYIDFEKGKDSIPT-UHFFFAOYSA-N 5-(5-amino-2h-pyrrol-4-yl)-4-(2-chloro-4-iodoanilino)-2-fluorobenzenesulfonamide Chemical compound NC1=NCC=C1C1=CC(S(N)(=O)=O)=C(F)C=C1NC1=CC=C(I)C=C1Cl LYIDFEKGKDSIPT-UHFFFAOYSA-N 0.000 description 1
- BJRPARRNOUWNFK-UHFFFAOYSA-N 5-[3,4-difluoro-2-(4-iodo-2-methylanilino)phenyl]-1,2-dihydropyrazol-3-one Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=CC=C1C1=CC(O)=NN1 BJRPARRNOUWNFK-UHFFFAOYSA-N 0.000 description 1
- MJTBYZMYYIMRQJ-UHFFFAOYSA-N 5-[4-fluoro-2-(4-iodo-2-methylanilino)-5-nitrophenyl]-1,2-dihydro-1,2,4-triazol-3-one Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=C([N+]([O-])=O)C=C1C1=NN=C(O)N1 MJTBYZMYYIMRQJ-UHFFFAOYSA-N 0.000 description 1
- XTZXRXGVCIMKOH-UHFFFAOYSA-N 5-[4-fluoro-2-(4-iodo-2-methylanilino)-5-nitrophenyl]-1,2-dihydro-1,2,4-triazole-3-thione Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=C([N+]([O-])=O)C=C1C1=NN=C(S)N1 XTZXRXGVCIMKOH-UHFFFAOYSA-N 0.000 description 1
- JQANBYCJVOUVHD-UHFFFAOYSA-N 5-[5-(4-iodoanilino)-1,3-benzoxazol-6-yl]-3h-1,3,4-oxadiazol-2-one Chemical compound O1C(O)=NN=C1C(C(=C1)NC=2C=CC(I)=CC=2)=CC2=C1N=CO2 JQANBYCJVOUVHD-UHFFFAOYSA-N 0.000 description 1
- IMEQITCXVWTPDH-UHFFFAOYSA-N 5-[5-(4-iodoanilino)-1-benzofuran-6-yl]-3h-1,3,4-oxadiazol-2-one Chemical compound O1C(O)=NN=C1C(C(=C1)NC=2C=CC(I)=CC=2)=CC2=C1C=CO2 IMEQITCXVWTPDH-UHFFFAOYSA-N 0.000 description 1
- JNZYMWCOJSHVFX-UHFFFAOYSA-N 5-[5-(4-iodoanilino)-1h-indol-6-yl]-3h-1,3,4-oxadiazol-2-one Chemical compound O1C(O)=NN=C1C(C(=C1)NC=2C=CC(I)=CC=2)=CC2=C1C=CN2 JNZYMWCOJSHVFX-UHFFFAOYSA-N 0.000 description 1
- TXCREFAPTIFOGU-UHFFFAOYSA-N 5-[6-(4-iodo-2-methylanilino)-3h-benzimidazol-5-yl]-3h-1,3,4-oxadiazol-2-one Chemical compound CC1=CC(I)=CC=C1NC(C(=C1)C=2OC(O)=NN=2)=CC2=C1N=CN2 TXCREFAPTIFOGU-UHFFFAOYSA-N 0.000 description 1
- FVKPWVWNXVCGGZ-UHFFFAOYSA-N 5-[6-(4-iodoanilino)-1-benzofuran-5-yl]-3h-1,3,4-oxadiazol-2-one Chemical compound O1C(O)=NN=C1C(C(=C1)NC=2C=CC(I)=CC=2)=CC2=C1OC=C2 FVKPWVWNXVCGGZ-UHFFFAOYSA-N 0.000 description 1
- IRYUCXPLMVMFGS-UHFFFAOYSA-N 5-[6-(4-iodoanilino)-1-benzothiophen-5-yl]-3h-1,3,4-oxadiazol-2-one Chemical compound O1C(O)=NN=C1C(C(=C1)NC=2C=CC(I)=CC=2)=CC2=C1SC=C2 IRYUCXPLMVMFGS-UHFFFAOYSA-N 0.000 description 1
- XQIBXXKWUXUQHR-UHFFFAOYSA-N 5-[7-fluoro-6-(4-iodo-2-methylanilino)-1,3-benzoxazol-5-yl]-3h-1,3,4-oxadiazol-2-one Chemical compound CC1=CC(I)=CC=C1NC(C(=C1)C=2OC(O)=NN=2)=C(F)C2=C1N=CO2 XQIBXXKWUXUQHR-UHFFFAOYSA-N 0.000 description 1
- HULDRQRKKXRXBI-UHFFFAOYSA-N 5-chloro-2-methoxybenzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(O)=O HULDRQRKKXRXBI-UHFFFAOYSA-N 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- PVOCXOMOHDQDKH-UHFFFAOYSA-N C1=CC(=C(C(=C1C2=NNC(=O)S2)S(=O)(=O)N)F)F Chemical compound C1=CC(=C(C(=C1C2=NNC(=O)S2)S(=O)(=O)N)F)F PVOCXOMOHDQDKH-UHFFFAOYSA-N 0.000 description 1
- DTQNDZKCAMGGDF-UHFFFAOYSA-N C1=CC=C(C(=C1)C2=NC(=NN2)N)S(=O)(=O)N Chemical compound C1=CC=C(C(=C1)C2=NC(=NN2)N)S(=O)(=O)N DTQNDZKCAMGGDF-UHFFFAOYSA-N 0.000 description 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- DKARYSOQJQJOIM-UHFFFAOYSA-N CC1=C(C=CC(=C1)I)NC2=CC=CC=C2C(=O)NN Chemical compound CC1=C(C=CC(=C1)I)NC2=CC=CC=C2C(=O)NN DKARYSOQJQJOIM-UHFFFAOYSA-N 0.000 description 1
- JIPMATZRMPAVCO-UHFFFAOYSA-N CC1=CC(I)=CC=C1NC1=C(F)C(F)=CC=C1C1=C(O)N(C)N=N1 Chemical compound CC1=CC(I)=CC=C1NC1=C(F)C(F)=CC=C1C1=C(O)N(C)N=N1 JIPMATZRMPAVCO-UHFFFAOYSA-N 0.000 description 1
- JAWDABZODJMKEM-UHFFFAOYSA-N CC1=CC(I)=CC=C1NC1=CC(F)=C(S(N)(=O)=O)C=C1C1=C(O)N(C)N=C1 Chemical compound CC1=CC(I)=CC=C1NC1=CC(F)=C(S(N)(=O)=O)C=C1C1=C(O)N(C)N=C1 JAWDABZODJMKEM-UHFFFAOYSA-N 0.000 description 1
- CHCIQDCYJCNHFR-UHFFFAOYSA-N CN1C=NC2=C1C=C(C(=C2)C3=NN=CO3)NC4=C(C=C(C=C4)I)Cl Chemical compound CN1C=NC2=C1C=C(C(=C2)C3=NN=CO3)NC4=C(C=C(C=C4)I)Cl CHCIQDCYJCNHFR-UHFFFAOYSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 241000506654 Haemulon album Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 description 1
- 108060006687 MAP kinase kinase kinase Proteins 0.000 description 1
- 101150040099 MAP2K2 gene Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229910014299 N-Si Inorganic materials 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- NPKISZUVEBESJI-AWEZNQCLSA-N N-benzoyl-L-phenylalanine Chemical class C([C@@H](C(=O)O)NC(=O)C=1C=CC=CC=1)C1=CC=CC=C1 NPKISZUVEBESJI-AWEZNQCLSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- UOQFAFZVQSFLCZ-UHFFFAOYSA-N NC(=O)C1=NNC(O)=N1 Chemical class NC(=O)C1=NNC(O)=N1 UOQFAFZVQSFLCZ-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 229920003189 Nylon 4,6 Polymers 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 102000014750 Phosphorylase Kinase Human genes 0.000 description 1
- 108010064071 Phosphorylase Kinase Proteins 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- GNVMUORYQLCPJZ-UHFFFAOYSA-M Thiocarbamate Chemical compound NC([S-])=O GNVMUORYQLCPJZ-UHFFFAOYSA-M 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010047627 Vitamin deficiencies Diseases 0.000 description 1
- XAKBSHICSHRJCL-UHFFFAOYSA-N [CH2]C(=O)C1=CC=CC=C1 Chemical group [CH2]C(=O)C1=CC=CC=C1 XAKBSHICSHRJCL-UHFFFAOYSA-N 0.000 description 1
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
- COPSSKKGQYBGGP-UHFFFAOYSA-N [O-]/C(\O)=[S+]\CC1=CC=CC=C1 Chemical compound [O-]/C(\O)=[S+]\CC1=CC=CC=C1 COPSSKKGQYBGGP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000007824 aliphatic compounds Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000005741 alkyl alkenyl group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000005021 aminoalkenyl group Chemical group 0.000 description 1
- 125000005014 aminoalkynyl group Chemical group 0.000 description 1
- 125000005124 aminocycloalkyl group Chemical group 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- UOCJDOLVGGIYIQ-PBFPGSCMSA-N cefatrizine Chemical group S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](N)C=2C=CC(O)=CC=2)CC=1CSC=1C=NNN=1 UOCJDOLVGGIYIQ-PBFPGSCMSA-N 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-M chloroacetate Chemical compound [O-]C(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-M 0.000 description 1
- 229940089960 chloroacetate Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- JAWGVVJVYSANRY-UHFFFAOYSA-N cobalt(3+) Chemical compound [Co+3] JAWGVVJVYSANRY-UHFFFAOYSA-N 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-M crotonate Chemical compound C\C=C\C([O-])=O LDHQCZJRKDOVOX-NSCUHMNNSA-M 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 229940120124 dichloroacetate Drugs 0.000 description 1
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000773 effect on pain Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000003106 haloaryl group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000035990 intercellular signaling Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- HZVPJXOQDCOJRJ-UHFFFAOYSA-N isoxazolin-5-one Chemical compound O=C1C=CNO1 HZVPJXOQDCOJRJ-UHFFFAOYSA-N 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940058352 levulinate Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- RMIODHQZRUFFFF-UHFFFAOYSA-M methoxyacetate Chemical compound COCC([O-])=O RMIODHQZRUFFFF-UHFFFAOYSA-M 0.000 description 1
- KSSDATBGROGULK-UHFFFAOYSA-N methyl 2-phenylethaneperoxoate Chemical compound COOC(=O)CC1=CC=CC=C1 KSSDATBGROGULK-UHFFFAOYSA-N 0.000 description 1
- QZHVJQPDGJBDOK-UHFFFAOYSA-N methyl 3,4-difluoro-2-(4-iodo-2-methylanilino)benzoate Chemical compound COC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1C QZHVJQPDGJBDOK-UHFFFAOYSA-N 0.000 description 1
- 150000005217 methyl ethers Chemical class 0.000 description 1
- NYEBKUUITGFJAK-UHFFFAOYSA-N methylsulfanylmethanethioic s-acid Chemical compound CSC(O)=S NYEBKUUITGFJAK-UHFFFAOYSA-N 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 101150068383 mkk2 gene Proteins 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- 230000007433 nerve pathway Effects 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 125000004971 nitroalkyl group Chemical group 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OIPZNTLJVJGRCI-UHFFFAOYSA-M octadecanoyloxyaluminum;dihydrate Chemical compound O.O.CCCCCCCCCCCCCCCCCC(=O)O[Al] OIPZNTLJVJGRCI-UHFFFAOYSA-M 0.000 description 1
- 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229940039748 oxalate Drugs 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000005429 oxyalkyl group Chemical group 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000006505 p-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C#N)C([H])([H])* 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxyacetic acid Chemical compound OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 description 1
- 125000006187 phenyl benzyl group Chemical group 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- PWXJULSLLONQHY-UHFFFAOYSA-N phenylcarbamic acid Chemical compound OC(=O)NC1=CC=CC=C1 PWXJULSLLONQHY-UHFFFAOYSA-N 0.000 description 1
- FAQJJMHZNSSFSM-UHFFFAOYSA-N phenylglyoxylic acid Chemical compound OC(=O)C(=O)C1=CC=CC=C1 FAQJJMHZNSSFSM-UHFFFAOYSA-N 0.000 description 1
- NIXKBAZVOQAHGC-UHFFFAOYSA-N phenylmethanesulfonic acid Chemical compound OS(=O)(=O)CC1=CC=CC=C1 NIXKBAZVOQAHGC-UHFFFAOYSA-N 0.000 description 1
- 125000001639 phenylmethylene group Chemical group [H]C(=*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 125000004591 piperonyl group Chemical group C(C1=CC=2OCOC2C=C1)* 0.000 description 1
- 125000005547 pivalate group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 208000018316 severe headache Diseases 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- LMYRWZFENFIFIT-UHFFFAOYSA-N toluene-4-sulfonamide Chemical compound CC1=CC=C(S(N)(=O)=O)C=C1 LMYRWZFENFIFIT-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229940066528 trichloroacetate Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- CPRPKIMXLHBUGA-UHFFFAOYSA-N triethyltin Chemical group CC[Sn](CC)CC CPRPKIMXLHBUGA-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14440399P | 1999-07-16 | 1999-07-16 | |
US60/144,403 | 1999-07-16 | ||
PCT/US2000/018346 WO2001005391A2 (en) | 1999-07-16 | 2000-07-05 | Method for treating chronic pain using mek inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20020015379A true KR20020015379A (ko) | 2002-02-27 |
Family
ID=22508429
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020027000665A KR20020015379A (ko) | 1999-07-16 | 2000-07-05 | 엠이케이 억제제를 사용하는 만성 동통의 치료방법 |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1202732A2 (es) |
JP (1) | JP2003504399A (es) |
KR (1) | KR20020015379A (es) |
CN (1) | CN1358095A (es) |
AU (1) | AU5785900A (es) |
CA (1) | CA2377100A1 (es) |
CO (1) | CO5190702A1 (es) |
HK (1) | HK1047039A1 (es) |
HU (1) | HUP0202381A3 (es) |
IL (1) | IL147617A0 (es) |
PE (1) | PE20010547A1 (es) |
PL (1) | PL352705A1 (es) |
TR (1) | TR200200204T2 (es) |
UY (1) | UY26248A1 (es) |
WO (1) | WO2001005391A2 (es) |
ZA (1) | ZA200109903B (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
HUE025767T2 (en) | 2002-03-13 | 2016-05-30 | Array Biopharma Inc | N3-alkylated benzimidazole derivatives as MEK inhibitors |
US20050004186A1 (en) * | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
US7538120B2 (en) | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
KR101013932B1 (ko) | 2003-10-21 | 2011-02-14 | 워너-램버트 캄파니 엘엘씨 | N-[(r)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도페닐아미노)-벤자미드 다형체 형태 |
US7732616B2 (en) | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
AU2004293019B2 (en) | 2003-11-19 | 2010-10-28 | Array Biopharma Inc. | Bicyclic inhibitors of MEK and methods of use thereof |
EP1684694A2 (en) | 2003-11-21 | 2006-08-02 | Array Biopharma, Inc. | Akt protein kinase inhibitors |
EP1802579B1 (en) | 2004-10-20 | 2013-11-20 | Merck Serono SA | Derivatives of 3-arylaminopyridine |
ES2405785T3 (es) | 2005-05-18 | 2013-06-03 | Array Biopharma Inc. | Inhibidores heterocíclicos de MEK y métodos de uso de los mismos |
NZ567140A (en) | 2005-10-07 | 2011-09-30 | Exelixis Inc | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
CA2656618C (en) | 2006-07-06 | 2014-08-26 | Array Biopharma Inc. | Cyclopenta [d] pyrimidines as akt protein kinase inhibitors |
US8063050B2 (en) | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
ATE493418T1 (de) | 2006-07-06 | 2011-01-15 | Array Biopharma Inc | Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren |
EP2054418B1 (en) | 2006-07-06 | 2011-11-09 | Array Biopharma Inc. | Dihydrothieno pyrimidines as akt protein kinase inhibitors |
WO2008066131A1 (fr) * | 2006-12-01 | 2008-06-05 | Banyu Pharmaceutical Co., Ltd. | Nouveau dérivé de phényl-isoxazol-3-ol |
CN101605540A (zh) | 2006-12-14 | 2009-12-16 | 埃克塞利希斯股份有限公司 | 使用mek抑制剂的方法 |
AU2008206045A1 (en) * | 2007-01-19 | 2008-07-24 | Ardea Biosciences, Inc. | Inhibitors of MEK |
US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
JP5542282B2 (ja) | 2007-07-05 | 2014-07-09 | アレイ バイオファーマ、インコーポレイテッド | Aktプロテインキナーゼ阻害剤としてのピリミジルシクロペンタン |
CN101801955B (zh) | 2007-07-05 | 2013-05-08 | 阵列生物制药公司 | 作为akt蛋白激酶抑制剂的嘧啶基环戊烷 |
AU2009204025B2 (en) | 2008-01-09 | 2014-02-20 | Array Biopharma Inc. | Hydroxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
AU2009204019B2 (en) | 2008-01-09 | 2014-02-20 | Array Biopharma Inc. | Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor |
ES2399384T3 (es) | 2008-11-10 | 2013-04-01 | Bayer Schering Pharma Ag | Sulfonamido fenoxibenzamidas sustituidas |
EP2491016A1 (en) | 2009-10-21 | 2012-08-29 | Bayer Pharma Aktiengesellschaft | Substituted benzosulphonamides |
WO2011047788A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Schering Pharma Aktiengesellschaft | Substituted benzosulphonamides |
EP2491014A1 (en) | 2009-10-21 | 2012-08-29 | Bayer Pharma Aktiengesellschaft | Substituted halophenoxybenzamide derivatives |
EP2632899A1 (en) | 2010-10-29 | 2013-09-04 | Bayer Intellectual Property GmbH | Substituted phenoxypyridines |
RU2631240C2 (ru) | 2011-04-01 | 2017-09-20 | Дженентек, Инк. | Комбинации соединений-ингибиторов акт и абиратерона, и способы применения |
MX2013011333A (es) | 2011-04-01 | 2014-04-16 | Genentech Inc | Combinaciones de compuestos inhibidores de akt y mek, y metodos de uso. |
SI2909188T1 (en) | 2012-10-12 | 2018-07-31 | Exelixis, Inc. | A novel process for the manufacture of compounds for use in the treatment of cancer |
EP3618818A4 (en) | 2017-05-03 | 2020-12-09 | Vivace Therapeutics, Inc. | NON-CONDENSED TRICYCLIC COMPOUNDS |
CA3073543A1 (en) | 2017-08-21 | 2019-02-28 | Vivace Therapeutics, Inc. | Benzosulfonyl compounds |
WO2019113236A1 (en) | 2017-12-06 | 2019-06-13 | Vivace Therapeutics, Inc. | Benzocarbonyl compounds |
EP3793551A4 (en) | 2018-05-16 | 2022-01-26 | Vivace Therapeutics, Inc. | OXADIAZOLE COMPOUNDS |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6251943B1 (en) * | 1997-02-28 | 2001-06-26 | Warner-Lambert Company | Method of treating or preventing septic shock by administering a MEK inhibitor |
DE69836378T2 (de) * | 1997-07-01 | 2007-10-11 | Warner-Lambert Co. Llc | Benzoesäure- und Benzamid-Derivate von Anthranilsäure und ihre Anwendung als MEK-Inhibitoren |
HUP0104693A3 (en) * | 1998-12-16 | 2003-12-29 | Warner Lambert Co | Treatment of arthritis with mek inhibitors |
WO2000042029A1 (en) * | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | 1-heterocycle substituted diarylamines |
-
2000
- 2000-07-05 WO PCT/US2000/018346 patent/WO2001005391A2/en not_active Application Discontinuation
- 2000-07-05 AU AU57859/00A patent/AU5785900A/en not_active Abandoned
- 2000-07-05 HU HU0202381A patent/HUP0202381A3/hu unknown
- 2000-07-05 TR TR2002/00204T patent/TR200200204T2/xx unknown
- 2000-07-05 KR KR1020027000665A patent/KR20020015379A/ko not_active Application Discontinuation
- 2000-07-05 PL PL00352705A patent/PL352705A1/xx unknown
- 2000-07-05 JP JP2001510448A patent/JP2003504399A/ja active Pending
- 2000-07-05 EP EP00943382A patent/EP1202732A2/en not_active Withdrawn
- 2000-07-05 IL IL14761700A patent/IL147617A0/xx unknown
- 2000-07-05 CN CN00809525A patent/CN1358095A/zh active Pending
- 2000-07-05 CA CA002377100A patent/CA2377100A1/en not_active Abandoned
- 2000-07-14 CO CO00053308A patent/CO5190702A1/es not_active Application Discontinuation
- 2000-07-14 PE PE2000000703A patent/PE20010547A1/es not_active Application Discontinuation
- 2000-07-14 UY UY26248A patent/UY26248A1/es not_active Application Discontinuation
-
2001
- 2001-11-30 ZA ZA200109903A patent/ZA200109903B/xx unknown
-
2002
- 2002-11-29 HK HK02108607.6A patent/HK1047039A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CN1358095A (zh) | 2002-07-10 |
HUP0202381A3 (en) | 2004-12-28 |
IL147617A0 (en) | 2002-08-14 |
WO2001005391A3 (en) | 2001-07-19 |
ZA200109903B (en) | 2003-05-28 |
CA2377100A1 (en) | 2001-01-25 |
CO5190702A1 (es) | 2002-08-29 |
HUP0202381A2 (hu) | 2002-11-28 |
PE20010547A1 (es) | 2001-06-04 |
UY26248A1 (es) | 2000-10-31 |
WO2001005391A2 (en) | 2001-01-25 |
HK1047039A1 (zh) | 2003-02-07 |
AU5785900A (en) | 2001-02-05 |
PL352705A1 (en) | 2003-09-08 |
EP1202732A2 (en) | 2002-05-08 |
TR200200204T2 (tr) | 2002-11-21 |
JP2003504399A (ja) | 2003-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20020015379A (ko) | 엠이케이 억제제를 사용하는 만성 동통의 치료방법 | |
US6545030B1 (en) | 1-heterocycle substituted diarylamines | |
DE60005688T2 (de) | Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer | |
KR20020015376A (ko) | Mek 억제제를 사용한 만성 통증의 치료 방법 | |
JP2003504400A (ja) | Mek阻害剤を用いた慢性痛の治療方法 | |
AU2003231142B2 (en) | Compositions and their uses for alleviating pain | |
US6506798B1 (en) | 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors | |
US7030119B1 (en) | Method for treating chronic pain using MEK inhibitors | |
UA72239C2 (en) | Substituted 1-heterocyclic diarylamines | |
JP2000212141A (ja) | ジアリ―ルアミン | |
JP2004503535A (ja) | インドールおよびベンゾイミダゾール15−リポキシゲナーゼ阻害剤 | |
JP2001055376A (ja) | ジアリールアミン | |
JP2000212157A (ja) | ジアリ―ルアミン | |
MXPA01006659A (es) | Diarilaminas 1-heterociclicas substituidas | |
EP1280523A2 (en) | Use of benzamide derivatives for the treatment of high ocular tension and glaucoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |